Please assess the completion status of the following clinical trial:

Trial Title: Genetic-specific Effects of Fructose on Liver Lipogenesis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects 12 - 40 years~2. No history of alcohol abuse (\> 7 drinks per week)~3. History of fructose intake of \< 14 drinks per week~4. Caucasian ethnicity~5. BMI \> 25kg/m² - 32kg/m² or 85th -99th percentile but otherwise healthy~Exclusion Criteria:~1. ages \< 12 and \> 40 years~2. Pregnant/lactating~3. known alcohol abuse or fructose intake \> 14 drinks per week~4. not of Caucasian ethnicity~5. glucose levels \> 100 mg/dL if fasting, \> 140mg/dL if within 2 hours post meal and \> 200 mg/dL if random sample~6. taking anti-hypertensive, anti-diabetic, uric acid and/or lipid-lowering medications~7. known diagnosis of diabetes, fructose intolerance, chronic kidney disease, NAFLD or any liver-related disease, hypertriglyceridemia, polycystic ovary syndrome, hypothyroidism, obstructive sleep apnea, hypopituitarism and hypogonadism~8. BMI \< 25kg/m² or \> 32 kg/m² or \< 85th or \> 99th percentile~9. Liver fat fraction \>5% as per baseline MRI scan

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- High GRS group (Type: EXPERIMENTAL): This group consists of individuals who are in the highest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.
- Low GRS group (Type: EXPERIMENTAL): This groups consists of individuals who are in the lowest quartile of the genetic risk score (GRS) and will ingest one sugar drink (equal to 2 soft drinks) per day for 3 weeks. The GRS is computed by adding the number of alleles that increase the risk for liver lipogenesis or fatty liver.

Based on this trial design, predict the completion outcome and termination type (if applicable).